215 related articles for article (PubMed ID: 26426829)
1. A Chimeric Cetuximab-Functionalized Corona as a Potent Delivery System for Microtubule-Destabilizing Nanocomplexes to Hepatocellular Carcinoma Cells: A Focus on EGFR and Tubulin Intracellular Dynamics.
Poojari R; Kini S; Srivastava R; Panda D
Mol Pharm; 2015 Nov; 12(11):3908-23. PubMed ID: 26426829
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial cetuximab targeted polymeric nanocomplexes reduce PRC1 level and abrogate growth of metastatic hepatocellular carcinoma in vivo with efficient radionuclide uptake.
Poojari R; Mohanty B; Kadwad V; Suryawanshi D; Chaudhari P; Khade B; Srivastava R; Gupta S; Panda D
Nanomedicine; 2022 Apr; 41():102529. PubMed ID: 35104671
[TBL] [Abstract][Full Text] [Related]
3. Andrographolide-loaded PLGA-PEG-PLGA micelles to improve its bioavailability and anticancer efficacy.
Zhang J; Li Y; Gao W; Repka MA; Wang Y; Chen M
Expert Opin Drug Deliv; 2014 Sep; 11(9):1367-80. PubMed ID: 24935153
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic effect of a multi-targeted imidazolium compound in hepatocellular carcinoma.
Gopalan B; Narayanan K; Ke Z; Lu T; Zhang Y; Zhuo L
Biomaterials; 2014 Aug; 35(26):7479-87. PubMed ID: 24912819
[TBL] [Abstract][Full Text] [Related]
5. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
7. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
Zhang J; Zhang M; Ji J; Fang X; Pan X; Wang Y; Wu C; Chen M
Pharm Res; 2015 Oct; 32(10):3376-90. PubMed ID: 26148773
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab-conjugated iron oxide nanoparticles for cancer imaging and therapy.
Tseng SH; Chou MY; Chu IM
Int J Nanomedicine; 2015; 10():3663-85. PubMed ID: 26056447
[TBL] [Abstract][Full Text] [Related]
9. NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma.
Chen W; Shen X; Xia X; Xu G; Ma T; Bai X; Liang T
Liver Int; 2012 Jan; 32(1):70-7. PubMed ID: 22098470
[TBL] [Abstract][Full Text] [Related]
10. Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma.
Zhao B; Dong Z; Liu W; Lou F; Wang Q; Hong H; Wang Y
J Nanobiotechnology; 2021 May; 19(1):124. PubMed ID: 33933077
[TBL] [Abstract][Full Text] [Related]
11. Stepwise pH-responsive nanoparticles containing charge-reversible pullulan-based shells and poly(β-amino ester)/poly(lactic-co-glycolic acid) cores as carriers of anticancer drugs for combination therapy on hepatocellular carcinoma.
Zhang C; An T; Wang D; Wan G; Zhang M; Wang H; Zhang S; Li R; Yang X; Wang Y
J Control Release; 2016 Mar; 226():193-204. PubMed ID: 26896737
[TBL] [Abstract][Full Text] [Related]
12. Liposomes as Delivery System of a Sn(IV) Complex for Cancer Therapy.
Corvo ML; Mendo AS; Figueiredo S; Gaspar R; Larguinho M; Guedes da Silva MF; Baptista PV; Fernandes AR
Pharm Res; 2016 Jun; 33(6):1351-8. PubMed ID: 27033349
[TBL] [Abstract][Full Text] [Related]
13. Distinct stratification of normal liver, hepatocellular carcinoma (HCC), and anticancer nanomedicine-treated- tumor tissues by Raman fingerprinting for HCC therapeutic monitoring.
Poojari R; Bhujbal M; Hole A; Murali Krishna C
Nanomedicine; 2021 Apr; 33():102352. PubMed ID: 33418135
[TBL] [Abstract][Full Text] [Related]
14. SP94 Peptide-Functionalized PEG-PLGA Nanoparticle Loading with Cryptotanshinone for Targeting Therapy of Hepatocellular Carcinoma.
Nie X; Liu Y; Li M; Yu X; Yuan W; Huang S; Ren D; Wang Y; Wang Y
AAPS PharmSciTech; 2020 Apr; 21(4):124. PubMed ID: 32342227
[TBL] [Abstract][Full Text] [Related]
15. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
16. Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma.
Wang Y; Yu H; Zhang D; Wang G; Song W; Liu Y; Ma S; Tang Z; Liu Z; Sakurai K; Chen X
Acta Biomater; 2019 Jul; 92():229-240. PubMed ID: 31100462
[TBL] [Abstract][Full Text] [Related]
17. Intracellular trafficking and cellular uptake mechanism of mPEG-PLGA-PLL and mPEG-PLGA-PLL-Gal nanoparticles for targeted delivery to hepatomas.
Liu P; Sun Y; Wang Q; Sun Y; Li H; Duan Y
Biomaterials; 2014 Jan; 35(2):760-70. PubMed ID: 24148242
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Wang Y; Zhou J; Qiu L; Wang X; Chen L; Liu T; Di W
Biomaterials; 2014 May; 35(14):4297-309. PubMed ID: 24565522
[TBL] [Abstract][Full Text] [Related]
19. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway.
Li T; Dong ZR; Guo ZY; Wang CH; Zhi XT; Zhou JW; Li DK; Chen ZT; Chen ZQ; Hu SY
Liver Int; 2015 Apr; 35(4):1416-29. PubMed ID: 25066210
[TBL] [Abstract][Full Text] [Related]
20. Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab')(2) for hepatocellular carcinoma.
Jin C; Qian N; Zhao W; Yang W; Bai L; Wu H; Wang M; Song W; Dou K
Biomacromolecules; 2010 Sep; 11(9):2422-31. PubMed ID: 20831277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]